CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PRUSOGLIPTIN, DAPAGLIFLOZIN AND METFORMIN EXTENDED-RELEASE TABLETS OBTAIN CLINICAL TRIAL APPROVAL IN CHINA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that Prusogliptin, Dapagliflozin and Metformin Extended-Release Tablets (the "**Product**") developed by the Group have obtained approval from the National Medical Products Administration of the People's Republic of China to conduct clinical trials in China.

The Product is the world's first clinically approved triple-drug combination formulation consisting of prusogliptin, dapagliflozin and metformin hydrochloride. Prusogliptin is a dipeptidyl peptidase-4 ("**DPP-4**") inhibitor that elevates the level of endogenous active glucagon-like peptide-1 (GLP-1) by inhibiting DPP-4, thereby enhancing the sensitivity of β-cells and α-cells towards glucose, increasing glucose-stimulated insulin secretion, and strengthening the inhibitory effect of glucose on glucagon secretion, which in turn improves hyperglycemia. Dapagliflozin is a sodium-glucose co-transporter 2 ("**SGLT2**") inhibitor that reduces reabsorption of filtered glucose by inhibiting SGLT2, thereby promoting urinary glucose excretion. Metformin is a biguanide drug that improves glucose tolerance in patients with type 2 diabetes mellitus and lowers both basal blood glucose and postprandial blood glucose.

The indication for this clinical trial approval is: "The Product is used as an adjunct to diet and exercise for adult patients with type 2 diabetes mellitus who have inadequate glycemic control with metformin hydrochloride monotherapy. The triple-drug combination formulation has complementary mechanisms of action that cover multiple pathophysiological mechanisms of diabetes, enabling effective glycemic control with a favorable safety and tolerability profile. In addition, it can reduce the number of drugs taken, simplify antihyper glycemic regimen, and improve patient adherence, demonstrating high clinical development value. The Product will provide a new treatment option for patients with type 2 diabetes mellitus and further enrich the Group's pipeline in the field of metabolic diseases.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 29 December 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping and Mr. QU Zhiyong, as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.